Andere Sprachen Synaptogenix, Inc.

Aktien

A403YX

US87167T3005

SNPX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 01.07.2024			% 5 Tage	% 1. Jan.
4,15 ^USD	+1,22 %		-7,16 %	-38,95 %

26.06.	Synaptogenix gibt die FDA-Zulassung des IND-Antrags für eine klinische Studie für Bryostatin-1 bei Multipler Sklerose bekannt	CI
15.05.	Synaptogenix, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis	26.06.
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis	26.06.
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery	07.05.
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	24.04.
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	09.04.
Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	09.04.
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	03.04.
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	03.04.
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	19.12.
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	06.12.
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology	03.11.
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology	02.11.
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	02.11.
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28.09.23
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease	26.09.23
Synaptogenix : Certificate of Incorporation/Bylaws - Form 8-K	22.09.23
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study	07.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Synaptogenix, Inc.

Aktien

A403YX

US87167T3005

SNPX

Andere Sprachen

Filter